Song Jin

Song Jin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MZMo Zhou
Mo Zhou
YCYan Chen
Yan Chen
YGYanlei Gong
Yanlei Gong
MZMing-Qing Zhu
Ming-Qing Zhu
JCJiannong Cen
Jiannong Cen
LYLi Yao
Li Yao
Purpose: To evaluate the efficacy of next-generation sequencing (NGS) in minimal-residual-disease (MRD) monitoring in Chinese patients with multiple myeloma (MM). Methods: This study analyzed 60 Chinese MM patients. During MRD monitoring in these patients’ post-therapy, clonal immunoglobulin heavy chain (IGH) rearrangements were detected via NGS using LymphoTrack assays. MRD monitoring was performed using NGS or next-generation flow cytometry (NGF), and the results were compared. Additionally, the sensitivity and reproducibility of the NGS method were assessed. Results: The MRD detection range of the NGS method was 10–6–10–1, which suggested good linearity, with a Pearson correlation coefficient of 0.985 and a limit of detection of 10–6. Intra- and inter-assay reproducibility analyses showed that NGS exhibited 100% reproducibility with low variability in clonal cells. At diagnosis, unique clones were found in 42 patients (70.0%) with clonal IGH rearrangements, which were used as clonality markers for MRD monitoring post-therapy. Comparison of NGS and NGF for MRD monitoring showed 79.1% concordance. No samples that tested MRD-positive via NGF were found negative via NGS, indicating the higher sensitivity of NGS. MRD could be detected using NGS in 6 of 7 samples before autologous hematopoietic stem-cell transplantation, and 5 of them tested negative post-transplantation. In contrast, the NGF method could detect MRD in only 1 sample pre-transplantation. Conclusion: Compared with NGF, NGS exhibits higher sensitivity and reproducibility in MRD detection and can be an effective strategy for MRD monitoring in Chinese MM patients.

27 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SZShiyuan Zhou
Shiyuan Zhou
YZYingying Zhai
Yingying Zhai
LYLingzhi Yan
Lingzhi Yan
XSXiaolan Shi
Xiaolan Shi
JSJingjing Shang
Jingjing Shang
SJSong Jin
Song Jin
Background: Melphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM). Methods: A total of 105 newly diagnosed MM patients undergoing ASCT during May 2012 and August 2017 were retrospectively analyzed. The BU/CY regimen was applied to 64 patients. Busulfan (9.6 mg/kg or 8.0 mg/kg in total) and cyclophosphamide (3.6 g/m2 or 3.0 g/m2 in total) were administered according to the creatinine clearance rate (CCR). A high-dose melphalan (HDMEL) regimen (200 mg/m2) was given to the other 41 patients. Results: At a median follow-up of 65 (1~119) months, estimated overall survival (OS) and progression-free survival (PFS) at 104 months in the BU/CY and HDMEL groups were 35.6% vs. 20.5% (p = 0.263) and 20.2% vs. 2.4% (p = 0.035), respectively. The median overall survival (OS) and PFS of the HDMEL and BU/CY groups were 55 vs. 70.5 months and 26 vs. 46.5 months, respectively. In multivariate analysis, the BU/CY regimen was found to be the only protective factor for PFS. No lethal toxicity was found in the BU/CY group, and treatment-related mortality (TRM) in 100 days was similar to the HDMEL group. Conclusions: MM patients may also benefit from the dose-adjusted BU/CY regimen.

17 August 2025 in British Journal of Haematology
Verified
Journal Article
Open access
HYHongying You
Hongying You
WYWeiqin Yao
Weiqin Yao
LYLingzhi Yan
Lingzhi Yan
YZYingying Zhai
Yingying Zhai
ZYZhi Yan
Zhi Yan
CFChengcheng Fu
Chengcheng Fu
Summary: Del(1p32.3) by FISH detection in multiple myeloma (MM) has not been routinely carried out in China. Its clinical significance was not clearly demonstrated. This study analysed clinical characteristics, treatment response and prognostic significance of del(1p32.3). We analysed 345 newly diagnosed multiple myeloma (NDMM) samples, and cytogenetic analysis was performed using Cytoscan and FISH results, enabling comprehensive disease‐specific cohort analysis and prognostic model development. The total proportion of chromosomal 1 abnormality was 64.1%, including 189 cases of 1q21 gain/amplification and 88 cases of 1p deletion, 40 patients had 1p32.3/CDKN2Cdeletion. Del(1p32.3) patients were strongly correlated with 1q21 gain/amplification and 17p deletion. Del(1p32.3) patients were more likely accompanied with extra‐medullary multiple myeloma (EMM) and complex karyotype. Del(1p32.3) had a worse effect on progression‐free survival (PFS) and overall survival (OS), alongside other high‐risk cytogenetic abnormalities that further worsened prognosis, especially 1q gain/amplification. Patients with 1p32.3 in the main clone or with a single monoallelic deletion had significantly poorer survival outcomes. Autologous stem cell transplantation (ASCT) cannot completely overcome its adverse effects on prognosis. In multivariate analysis, 1p32.3 was an important independent adverse PFS factor. Patients harbouring single monoallelic del(1p32.3) and/or main clone deletions demonstrated inferior outcomes despite lenalidomide, bortezomib and dexamethasone (VRD) induction and transplantation. Del(1p32.3) had synergistic effects frequently co‐occurring with 1q21 gain/amplification, thus, we strongly advocate for routine del(1p32.3) testing in clinical practice.

14 April 2022 in Chinese Journal of Hematology
Verified
Journal Article
Open access
YLY Liu
Y Liu
HYH Y You
H Y You
LYL Z Yan
L Z Yan
SJSong Jin
Song Jin
JSJ J Shang
J J Shang
CFC C Fu
C C Fu
分析合并轻链型淀粉样变性(AL)的初诊多发性骨髓瘤(MM)患者的临床特征、疗效及预后。 回顾性分析苏州大学附属第一医院自2017年1月1日至2018年10月31日收治的160例初诊MM患者的临床资料。根据患者骨髓、皮肤和其他部位组织病理活检结果是否合并淀粉样变性分为两组,即合并淀粉样变性的MM(MM+AL)组和MM组,比较两组患者的临床特征及疗效。 160例初诊MM患者中,MM+AL组42例,MM组118例。在临床特征方面,MM+AL组的受累轻链与非受累轻链差值(dFLC)明显高于MM组(P=0.039)。诱导治疗后MM+AL组较MM组有更高的总缓解率(85.7%对79.7%,P<0.05)和非常好的部分缓解率(76.2%对55.1%,P<0.05)。中位随访26(0.25~41)个月,MM+AL组与MM组患者总生存(OS)和无进展生存的差异无统计学意义(P值均>0.05),自体造血干细胞移植组患者的OS优于未移植组患者(P值均<0.05)。MM+AL组心脏受累患者的预后较MM组和MM+AL组非心脏受累患者差(P<0.001),中位OS时间仅为13个月。 MM+AL患者和MM患者的鉴别诊断需行组织病理活检,尤其是dFLC明显增高患者。MM+AL组患者4个疗程诱导化疗后总体缓解率较MM组更高。MM+AL组累及心脏患者预后较差。

15 November 2022 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
YZYingying Zhai
Yingying Zhai
QWQingyuan Wang
Qingyuan Wang
YLYan Li
Yan Li
LLLimin Liu
Limin Liu
HZHuifen Zhou
Huifen Zhou
SJSong Jin
Song Jin

11 March 2016 in European Urology Supplements
Verified
Journal Article
Closed access
SJSong Jin
Song Jin
MDMingfan Dai
Mingfan Dai
ZLZhi-Min Liu
Zhi-Min Liu
JSJian-Guo Sun
Jian-Guo Sun
NXN. Xing
N. Xing
YNY. Niu
Y. Niu